Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study

BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are promising weight-loss drugs, but real-world data concerning the liability of GLP-1RAs in gastrointestinal safety are lacking. We examined the differences in gastrointestinal safety between semaglutide and liraglutide. MATER...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yu, Chen, Mingyu, Liu, Libin, Chen, Zhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763271/
https://www.ncbi.nlm.nih.gov/pubmed/35046686
http://dx.doi.org/10.2147/DMSO.S348025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763271/
https://www.ncbi.nlm.nih.gov/pubmed/35046686
http://dx.doi.org/10.2147/DMSO.S348025

Ejemplares similares